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Psoriasis is an inflammatory skin disorder that is inherited as a complex trait. Genetic studies have repeatedly
highlighted HLA-C as the major determinant for psoriasis susceptibility, with the Cw*0602 allele conferring
significant disease risk in a wide range of populations. Despite the potential importance of HLA-C variation in
psoriasis, either via an effect on peptide presentation or immuno-inhibitory activity, allele-specific expression
patterns have not been investigated. Here, we used reporter assays to characterize two regulatory variants,
which virtually abolished the response to tumor necrosis factor (TNF)-a (rs2524094) and IFN-g (rs10657191) in
HLA-Cw*0602 and a cluster of related alleles. We validated these findings through the analysis of HLA-Cw*0602
expression in primary keratinocytes treated with TNF-a and IFN-g. Finally, we showed that HLA-Cw*0602
transcripts are not increased in psoriatic skin lesions, despite highly elevated TNF-a levels. Thus, our findings
demonstrate the presence of allele-specific differences in HLA-C expression and indicate that HLA-Cw*0602 is
unresponsive to upregulation by key proinflammatory cytokines in psoriasis. These data pave the way for
functional studies into the pathogenic role of the major psoriasis susceptibility allele.
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INTRODUCTION
Psoriasis is a chronic, inflammatory skin disorder, affecting
approximately 2% of the Caucasian population. The disease is
characterized by keratinocyte hyperproliferation and altered
differentiation, in the presence of an inflammatory skin infiltrate,
typically consisting of dendritic cells, macrophages, T cells, and
neutrophils (Nestle et al., 2009). Psoriasis has a strong genetic
component and is widely regarded as a multifactorial disorder,
resulting from gene–gene and gene–environment interactions
(Griffiths and Barker, 2007; Liu et al., 2007).
A highly significant association between psoriasis and the
HLA-Cw6 antigen has long been established (Henseler and
Christophers, 1985; Mallon et al., 1999). In agreement with
these historical observations, genome-wide linkage scans
have repeatedly identified a primary disease susceptibility
locus (PSORS1), lying within the class I region of the major
histocompatibility complex, on chromosome 6p21.3 (Nair
et al., 1997; Trembath et al., 1997). Refinement studies, deep
sequencing experiments, and recent genome-wide associa-
tion data all point to HLA-C as the most likely PSORS1
gene (Veal et al., 2002; Nair et al., 2006; Liu et al., 2008;
Strange et al., 2010). However, the extended linkage
disequilibrium that characterizes the major histocompatibility
complex region has complicated the analysis of the
PSORS1 locus and has so far prevented the identification of
the casual susceptibility variant. At the same time, the
analysis of PSORS1 sequences associated with different
HLA-C alleles has demonstrated that the single-nucleotide
polymorphisms (SNPs) that are unique to HLA-Cw*0602
haplotypes lie exclusively in noncoding regions (Nair et al.,
2006).
In this context, the hypothesis driving this study is that the
PSORS1 disease susceptibility allele may lie within a
regulatory region influencing HLA-C expression. To explore
this pathogenic model, we investigated the differential
regulation of three HLA-C alleles, using reporter assays, in
combination with patient-based expression studies. This
integrated approach demonstrated the previously unreported
existence of allele-specific HLA-C expression patterns and
specifically identified two regulatory variants affecting the
response to IFN-g and tumor necrosis factor (TNF)-a.
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RESULTS
Two sequence variants in the HLA-C promoter cause
nonresponsiveness to TNF-a and IFNs
To assess the presence of HLA-Cw*0602-specific gene
expression patterns, we measured the reporter activity driven
by the HLA-Cw*0602, -Cw*0702, and -Cw*0304 promoters.
We examined a 426-bp fragment corresponding to the
gene minimal promoter (Johnson, 2003) and found that the
HLA-Cw*0602 reporter construct was significantly less active
than its HLA-Cw*0702 counterpart (Figure 1a). Importantly,
the HLA-C promoter contains an experimentally defined
enhancer kB element (Johnson and Pober, 1994), which
displays a G to A substitution (SNP rs2524094, see
Supplementary Figure S1 online) in HLA-Cw*0602 and in a
cluster of related alleles. To investigate whether this poly-
morphism was responsible for the differential activity of the
HLA-Cw*0602 and -Cw*0702 promoters, we repeated
the reporter assays following site-directed mutagenesis of
the HLA-Cw*0702 enhancer kB. These experiments revealed
a significant decrease in reporter activity for the mutagenized
construct (Figure 1b), thus confirming the functional impact
of the rs2524094 polymorphism.
To investigate whether SNP rs2524094 also affects
inducible promoter activity, we next carried out reporter
assays in cells that had been stimulated with TNF-a, IL-17A,
and IL-22, three inflammatory cytokines that signal through
the NF-kB pathway and have a key role in the pathogenesis
of psoriasis (Nickoloff et al., 2007). Surprisingly, none of the
examined HLA-C alleles responded to IL-17A or IL-22
treatment (Figure 1f). Conversely, the HLA-Cw*0702 promo-
ter displayed significant TNF-a–induced luciferase activity,
in keeping with the role of this cytokine as an inducer of
major histocompatibility complex gene expression (Johnson,
2003). At the same time, HLA-Cw*0602 showed a weak and
nonsignificant TNF-a response (Figure 1c). The analysis of
mutagenized constructs demonstrated that the introduction of
a wild-type rs2524094 allele in the HLA-Cw*0602 promoter
restored TNF-a responsiveness (Figure 1e). Conversely,
disruption of the HLA-Cw*0702 enhancer kB resulted in a
more modest TNF-a response (Figure 1d). Thus, the TNF-
a–induced activity of HLA-Cw*0702 is dependent on the
integrity of the enhancer kB element.
The HLA-C minimal promoter also contains an IFN
response stimulated element (ISRE), similar to the one
mediating IFN induction of the HLA-A and HLA-B genes
(Johnson, 2003). It is noteworthy that the HLA-C ISRE has a
different base composition in HLA-Cw*0602 and HLA-
Cw*0702, due to the occurrence of a 3 bp deletion in the
latter allele (-166_-163delTCT, rs10657191; Supplementary
Figure S1 online). Reporter assays showed that HLA-
Cw*0702, but not HLA-Cw*0602, could respond to IFN
stimulation. The analysis of a mutagenized construct con-
firmed that the ISRE deletion polymorphism was responsible
for this difference (Figure 1g and h).
Harboring the same kB and ISRE elements as HLA-
Cw*0602, HLA-Cw*0304 served as control and showed
similar reporter activity to HLA-Cw*0602 throughout all
experiments (Figure 1a, c, f, g and h).
Taken together, these results demonstrate that the
rs2524094 and the rs10657191 promoter variants affect
HLA-C cytokine responses, with the A and insertion alleles
determining nonresponsiveness to TNF-a and IFNs.
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Figure 1. HLA-C promoter variants determine nonresponsiveness of
HLA-Cw*0602 to TNF-a and IFNs. HeLa (a–f) or HEK293T (g–h) cells
were transfected with a luciferase gene under the control of wild-type
and mutagenized HLA-C promoters, along with a control reporter gene
encoding for b-galactosidase. (c–h) Transfected cells were treated with the
indicated cytokines for 24 hours and a dual-light reporter assay was
performed, in order to measure luciferase (luc) and b-galactosidase
(gal) activities. The results are expressed as the mean±SEM of luciferase/
b-galactosidase ratios. The Cw*06 luciferase/b-galactosidase ratio was
set as baseline to which all other measurements were normalized. Each
experiment was performed at least three times in triplicate. Statistical
significance was calculated using one-way analysis of variance (ANOVA,
a), t-test (b), or two-way ANOVA (c–h). ***Po0.001, **Po0.01, *Po0.05.
kBmut refers to the site-directed mutagenesis performed in the enhancer
kB of the -Cw*0602 and -Cw*0702 alleles. del-ISRE refers to the introduction
of a 3 bp deletion in the -Cw*0602 ISRE. ISRE, IFN response stimulated
element.
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TNF-a treatment of primary keratinocytes fails to upregulate
HLA-Cw*0602
Having established that the HLA-Cw*0602 promoter displays
reduced cytokine responses in reporter assays, we proceeded
to investigate HLA-C expression in cultured primary kerati-
nocytes. As the presence of inflammatory cytokines in
psoriatic skin would have confounded the interpretation of
our results, we carried out these experiments in cells isolated
from healthy donor skin samples. In keeping with the results
obtained in reporter assays, neither IL-17A nor IL-22 had a
significant effect on HLA-C expression, regardless of the
HLA-C genotype (Figure 2a, b and d). In both HLA-Cw*0602-
positive and -negative keratinocytes, IFN-g was the only
single cytokine that profoundly upregulated HLA-C
(Figure 2a and b). The strong synergistic effect of TNF-a in
combination with IFN-g as observed for donor N1 (Figure 2a)
was significantly reduced in HLA-Cw*0602-positive kerati-
nocytes (donor N2, Figure 2a). Following the validation
of antibody specificity (Supplementary Figure S2a online),
western blotting for HLA-C was performed, confirming the
mRNA data at the protein level (Figure 2b). To analyze
cytokine-induced HLA-C cell surface expression, immuno-
fluorescence staining was also performed on keratinocytes
from donor N1. The results confirmed IFN-g as the strongest
modulator of HLA-C expression (Figure 2c).
To specifically investigate the regulation of HLA-Cw*0602
transcripts, we next designed allele-specific, exon-spanning
primers (Supplementary Figure S2b online), which we used in
28
N1: Cw*02,*04 N2: Cw*06,*05
N2: Cw*06,*05 N3: Cw*06,*17 N4: Cw*06,*16 Total HLA-C
HLA-Cw*0602
***
*
Total HLA-C
HLA-Cw*0602 HLA-Cw*0602
HLA-C
***
m
R
N
A 
ex
pr
es
sio
n 
(fo
ld
 c
ha
ng
e) ***
***
24
20
16
12
8
4
0
28
m
R
N
A 
ex
pr
es
sio
n 
(fo
ld
 c
ha
ng
e)
m
R
N
A 
ex
pr
es
sio
n 
(fo
ld
 c
ha
ng
e)
m
R
N
A 
ex
pr
es
sio
n 
(fo
ld
 c
ha
ng
e)
24
20
20
18
14
10
8
6
2
16
16
12
12
8
4
4
0
0
m
R
N
A 
ex
pr
es
sio
n 
(fo
ld
 c
ha
ng
e) 20
18
14
10
8
6
2
16 ***
12
4
00
1
2
3
4
5
6
7
8
9
10
*
*
No
ne
IFN
-γ
IFN
-γ +
 TN
F-α IL-
22
IL-
17
A
TN
F-α No
ne
IFN
-γ
IFN
-γ +
 TN
F-α IL-
22
IL-
17
A
TN
F-α
N
on
e
IF
N
-γ
TN
F-
α
IF
N
-γ
 +
 T
N
F-
α
IL
-2
2
IL
-1
7A
N1
N1
HLA-C,
43 kDa
Hsp90,
90 kDa
N2
Isotype None IFN-γ TNF-α
No
ne
IFN
-γ
IL-
22
IL-
17
A
TN
F-αNo
ne
IFN
-γ
IL-
22
IL-
17
A
TN
F-αNo
ne
IFN
-γ
IL-
22
IL-
17
A
TN
F-α
Figure 2. Cytokine-induced HLA-C expression in primary keratinocytes. (a) Primary keratinocytes derived from healthy donors N1 and N2 were treated
with tumor necrosis factor (TNF)-a (10 ngml1), IFN-g (500Uml1), TNF-a (10 ngml1) þ IFN-g (500Uml1), IL-17A (10 ngml1), and IL-22 (10 ngml1)
for 24 hours or left untreated. For each condition, cells were split for RNA and protein isolation. HLA-C transcript levels were measured by real-time PCR
and normalized to the mean of cyclophylin A and Rplpo (large ribosomal protein) expression. HLA-C expression levels are plotted as fold changes
compared with the untreated control. Significance values were calculated using one-way analysis of variance. ***Po0.001, **Po0.01, *Po0.05. (b) 1% Triton
lysates of keratinocytes derived from donors N1 and N2 were analyzed for HLA-C protein expression by western blotting. (c) Immunofluorescence staining
of HLA-C. Cytokine-treated keratinocytes from donor N1 were deposited on glass slides by Cytospin and stained for HLA-C protein (red). Nuclei were
counterstained with 4,6-diamidino-2-phenylindole (blue). Bar¼ 50mm. (d) Total HLA-C and HLA-Cw*0602 mRNA levels were determined in primary
keratinocytes derived from three HLA-Cw*0602 heterozygous donors. Cytokine stimulation, RNA extraction, and complementary DNA synthesis were
carried out as described in a. Relative mRNA levels were expressed as fold change compared with the untreated control. White bars indicate total HLA-C
and green bars HLA-Cw*0602 expression. Significance values refer to differences in fold induction.
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real-time PCR measurements of gene expression. The results
of these experiments were again consistent with those
obtained in reporter assays. Total HLA-C and HLA-
Cw*0602 mRNA levels were both significantly upregulated
in response to IFN-g; however, HLA-Cw*0602 expression
was markedly less enhanced (Figure 2d). Moreover, TNF-a
treatment had no effect on HLA-Cw*0602 transcript levels,
and total HLA-C expression increased only in the cells
derived from donor N3 (Figure 2d,), whose non-risk allele
(Cw*17) carries a canonical enhancer kB sequence (Supple-
mentary Figure S1 online).
Thus, the analysis of endogenous HLA-Cw*0602 expres-
sion in human keratinocytes confirmed the nonresponsive-
ness to TNF-a, which we had observed in our reporter assays.
HLA-Cw*0602 expression levels do not differ significantly in
normal, peri-lesional, and lesional skin
In the final phase of this study, we investigated HLA-C
expression in whole tissue by analyzing total RNA isolated
from normal skin (N) (n¼ 31) and from matched pairs of peri-
lesional and lesional (L) psoriasis skin biopsies (n¼26). We
found that there was variation in non-risk HLA-C transcript
levels (Figures 3a), potentially reflecting the presence of
various combinations of regulatory elements in the different
non-risk alleles (Supplementary Table S1 online and Supple-
mentary Figures S1 and S3 online). In the genetically
homogenous HLA-Cw*0602 chromosome population, no
significant upregulation of HLA-Cw*0602 gene expression
was detected between normal, peri-lesional, and lesional
samples (Figure 3b), despite the presence of elevated TNF-a
and IFN-g levels in psoriatic skin (Supplementary Figure S4
online). The amount of total HLA-C protein found in the
epidermis was variable, but no evidence of upregulation was
observed in lesional (highlighted with an L in Figure 3c)
versus non-lesional (peri-lesional (PL)) samples, obtained
from HLA-Cw*0602 heterozygous individuals (Figure 3c).
Our data also show that there is no correlation between
HLA-C expression and psoriasis area and severity index score
(Supplementary Figure S5 online) and that transcript levels
are not affected by the use of topical or systemic therapeutic
agents (Supplementary Figure S6 online). Thus, our results are
unlikely to be confounded by individual variation in disease
severity or treatment.
Taken together, these findings are in agreement with the
notion of HLA-Cw*0602 nonresponsiveness to TNF-a, as they
show that HLA-Cw*0602 gene expression remains largely
unchanged in psoriatic skin, despite the presence of elevated
cytokine levels.
DISCUSSION
This study explores allele-specific patterns of HLA-C regula-
tion, using a combination of reductionist promoter assays and
studies in human tissue samples.
Our work was driven by the results of serologic studies,
which have long established an unequivocal association
between HLA-Cw6 and psoriasis (Henseler and Christophers,
1985; Mallon et al., 1999) and those of recent genome-wide
association scans, which have highlighted HLA-C as the most
likely PSORS1 candidate gene (Ellinghaus et al., 2010;
Strange et al., 2010; Stuart et al., 2010; Sun et al., 2010).
Because of its function as innate and adaptive immuno-
regulator, an involvement of HLA-C in psoriasis pathogenesis
is conceivable. HLA-Cw6 in particular has peptide-presenting
capacity (Falk et al., 1993; Dionne et al., 2004) and can
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Figure 3. HLA-C expression levels in normal and psoriatic skin. (a, b) HLA-C and HLA-Cw*0602 mRNA expression was measured in normal skin (N)
and in matched pairs of peri-lesional (PL) and lesional (L) psoriatic skin. (a) HLA-C expression in HLA-Cw*0602-negative samples of N (n¼21), PL (n¼10),
and L (n¼ 10) skin. (b) HLA-Cw*0602 expression in -Cw*0602 þ / samples of N (n¼ 10), PL (n¼ 16), and L (n¼ 16) skin. Real-time data are presented
as individual data points normalized to expression of the internal controls GAPDH (a) and b-actin (b). One-way analysis of variance statistical test was performed
for a and b yielding P-values 40.05. (c) Western blotting for HLA-C protein in the epidermis of normal and psoriatic skin. Green font indicates samples
heterozygous for HLA-Cw*0602, black font HLA-Cw*0602-negative samples.
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trigger CD8þ T-cell–specific responses (Dionne et al., 2004;
Johnston et al., 2004).
Although total HLA-C expression has previously been
investigated in psoriasis (Zhou et al., 2003; Carlen et al.,
2005, 2007; Nair et al., 2009), allele-specific patterns have
never been examined. In this context, our study provides
important insights into the regulation and expression of the
risk allele, HLA-Cw*0602, in normal, peri-lesional, and
lesional psoriatic skin.
We have used a combination of reporter and real-time
PCR assays to characterize a promoter variant (rs2524094)
mediating reduced responsiveness to TNF-a. We also investi-
gated an insertion/deletion polymorphism (rs10657191)
and found that it determined reduced sensitivity to IFNs
in reporter assays. However, this effect was not replicated
in real-time PCR experiments, where differential IFN
responses were observed in alleles sharing the same ISRE
element (Figure 2d). Thus, we suggest that other regulatory
elements outside of the HLA-C minimal promoter might be
of importance for the IFN response. We further argue that the
Th17 association with psoriasis (Di Cesare et al., 2009) is not
related to an effect on HLA-C transcript levels, as both IL-17A
and IL-22 failed to alter HLA-C promoter activity or
endogenous expression. Our observation that HLA-
Cw*0602 transcript levels do not differ significantly between
normal and psoriatic skin is in keeping with the above
findings, and further support the notion of HLA-Cw*0602
reduced responsiveness to proinflammatory cytokines.
It is worth pointing out that the rs2524094 variant is not
unique to HLA-Cw*0602, and thus other HLA-C alleles are
likely to show reduced responsiveness to TNF-a. In fact, our
reporter assays show that this is the case for HLA-Cw*0304,
which harbors the same enhancer kB element as HLA-
Cw*0602. At the same time, reduced responsiveness to TNF-
a is likely to have a different impact on risk and non-risk
HLA-C alleles, as they are likely to have differential affinities
for self-peptides and to interact with different binding
partners. For instance, the HLA-Cw6 (but not the HLA-Cw3)
protein has been shown to interact with KIR2DL1 inhibitory
receptor, which regulates the activity of natural killer and
T-cell subsets (Parham, 2005). It is noteworthy that associa-
tions between psoriasis and KIR receptor polymorphisms
have been reported in the past (Luszczek et al., 2004), with a
number of studies suggesting pathogenic and protective roles
for specific HLA-C/KIR genotype combinations (Nelson et al.,
2004; Holm et al., 2005). Further functional experiments will
now be required to explore the impact of TNF-a nonrespon-
siveness on HLA-C/KIR interactions and self-peptide pre-
sentation. Such studies hold the promise to elucidate the
molecular mechanisms underlying the contribution of HLA-
Cw*0602 to psoriasis susceptibility.
MATERIALS AND METHODS
Study population
Blood samples and skin biopsies were obtained from 26 patients
with plaque psoriasis (Supplementary Table S1 online). Control
skin tissue was obtained from 31 healthy volunteers undergoing
breast or abdominal reduction surgery. Our study was conducted in
accordance with the Declaration of Helsinki Principles, with
informed consent obtained from each volunteer and ethical approval
granted by the institutional review board of Guy’s Hospital.
Cell culture and cytokine stimulation assays
HeLa and HEK293T cell lines were cultured in DMEM medium
(Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum
(Sigma-Aldrich, St Louis, MO) and 1% penicillin/streptomycin (PAA,
Yeovil, Somerset, UK). LCL721.221-Cw*0602, LCL721.221-mock,
and HLA class I K562 transfectants were kindly provided by Dr
Matthias Marget (Institute of Immunology, University Medical Center
Schleswig-Holstein, Germany), and Dr Eric Champagne (INSERM
Toulouse, France), respectively; both LCL721.221 and K562 cells
were cultured in RPMI 1640 medium (Invitrogen) supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin.
Primary keratinocyte cell cultures were established using the
procedure described by Mee et al. (2007). Keratinocytes were
cultured for 2–4 passages in KGM-2 medium, in the presence of
growth supplements (KGM-2 Bullet Kit CC-3107, Lonza, Slough,
UK). For cytokine treatment, cells were stimulated for 24 hours with
either 10 ngml1 TNF-a, 500Uml1 IFN-g (PeproTech, London,
UK), 10 ngml1 IL-17A, or IL-22 (R&D Systems, Abingdon, UK).
Plasmids
Three BAC clones carrying HLA-C, but not HLA-A or HLA-B, were
used as templates for the specific amplification of the HLA-C
promoter. In particular, the BACs containing the Cw*0602 and
Cw*0702 promoters were selected from a library, which had been
previously generated from the leukocytes of a heterozygous psoriatic
patient, using the procedure described by Osoegawa et al. (2001). A
third BAC, which carries the HLA-Cw*0304 promoter, was kindly
provided by Dr Lucy Matthews (Wellcome Trust Sanger Institute,
Cambridge, UK). Allele-specific oligonucleotides tagged with XhoI
and HindIII (New England Biolabs, Hitchin, UK) restriction sites
were used to clone the minimal HLA-C promoter (Johnson, 2003)
into the pGL3-basic vector (Promega, Southampton, UK). Primer
sequences were HLA-C.F 50-AATCGCTCGAGAGGGACGGGGAT
TCCAGGAG-30, HLA-Cw*0602/*0304.R 50-AGGCAAGCTTCTCGG
CGTCTGGGGAGA-30, HLA-Cw*0702.R 50-AGGCAAGCTTCTC
GGCCTCTGGGGAGA-30.
Mutagenized constructs were generated using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA), according to
manufacturer’s instructions. The presence of the correct insert was
verified by direct sequencing of all wild-type and mutant constructs.
Transient transfection and dual-light reporter assay
HeLa or HEK293T cells were transfected with 1mg pGL3-basic
vector and 0.45 mg pJ7lacZ vector (kindly provided by Dr Talat
Nasim, King’s College London, UK), using the FuGene HD trans-
fection reagent (Roche, Mannheim, Germany). Cells were harvested
24 hours post transfection, and reporter gene expression was
measured with the Dual-Light luminescent reporter gene assay
(Applied Biosystems, Bedford, UK), according to the manufacturer’s
instructions.
RNA isolation and real-time PCR
Total RNA was isolated from cell lines and primary human keratino-
cytes using the RNeasy Plus Mini Kit (Qiagen, Crawley, UK) or TRI
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REAGENT (Sigma-Aldrich), according to the manufacturer’s protocol.
A measure of 500–1,000 ng total RNA was reverse transcribed into
complementary DNA, using SuperScript II Reverse Transcriptase
(Invitrogen) according to the manufacturers’ instructions.
Total HLA-C and HLA-Cw*0602 mRNA levels were assessed
by quantitative PCR (gene expression assay Hs03044135_m1) and
SYBR Green–based PCR, respectively. Primers for specific detection
of the HLA-Cw*0602 transcript were as follows: forward 50-TACTA
CAACCAGAGCGAGGA-30 and reverse 50-GGTCGCAGCCATACAT
CCA-30. PPIA, GAPDH b-actin transcripts were used as endogenous
controls. Samples were amplified on a Applied Biosystems 7900HT
Sequence Detection System, and real-time data were presented
either as individual data points normalized to the internal control
(2DCt) or expressed as fold change using the comparative Ct (2
DDCt)
method (Schmittgen and Livak, 2008).
HLA-C locus typing
Genomic DNA was extracted from peripheral blood or skin, using
the DNeasy Blood & Tissue Kit (Qiagen). Medium resolution HLA-C
typing was performed using PCR with sequence-specific primers
(Bunce et al., 1995).
Western blotting
Cell and tissue lysates were analyzed by western blotting, using
1mgml1 anti-HLA-C goat polyclonal antibody Q-18 (Santa Cruz
Biotechnology, CA) together with 1mgml1 anti-HSP90 rabbit mAb
H-114 (Santa Cruz Biotechnology) or anti-b-actin mouse mAb AC-15
(1:2,000, Sigma-Aldrich) as endogenous controls.
Cytospin and immunofluorescence
Cytospin (Cytospin 3 Cytocentrifuge, Thermo Fisher Scientific,
Loughborough, UK) was used to deposit monolayers of 2 105
primary human keratinocytes on glass slides. Cells were fixed
with acetone at 20 1C and incubated with HLA-C (Q18) goat
polyclonal IgG antibody (1:50 dilution) for 1 hour at room
temperature. Following incubation with donkey anti-goat Alexa
555 IgG antibody (1:200 dilution), cells were mounted with Prolong
Gold antifade reagent supplemented with 4,6-diamidino-2-pheny-
lindole (Invitrogen). Pictures were obtained using a fluorescent
microscope (Zeiss Axiophot Microscope, Carl Zeiss Jena GmbH,
Jena, Germany) with a camera (Nikon Digital Sight Camera, Nikon,
Tokyo, Japan).
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